Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niosomal Salbutamol Sulphate Inhaler Bioavailability
NCT03059017Phase 1Completed
- Sponsor
- The British University in Egypt
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of salbutamol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by The British University in Egypt. Primary endpoint: Maximum plasma concentration at 24 hours. Started Feb 2017; status: completed.
02
Drugs
salbutamol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03059017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059017.